Evidence Hub

Abstract 2716: Role for KMT2C mutation in endometrial cancer pathogenesis

Juveria Ali, Swornalata Pukhrambam, Sophia Agrusa, Areebah Qazi, Jessica Back, G. Dyson, Michele L. Cote, A. Gottschlich et al.

Cancer Research, 2025

Abstract

Endometrial cancer (EC) is the 4th most common cancer to be diagnosed in women. Although EC has reasonable survival rates, there is a disparity gap for African American (AA) women, as they are twice as likely to succumb to metastatic EC. They are also more likely to develop the more severe subtype, uterine serous carcinoma (USC), and high-grade EC. HER2-positive USC can be treated with Trastuzumab, but response varies. The KMT2C gene encodes a lysine methyltransferase involved in histone modification and transcriptional coactivation. Through a meta-analysis of multiple datasets, we identified KMT2C as highly mutated in High Grade Serous Endometrial Cancer (HGSEC) tumors from AA patients when compared to Non-Hispanic White patients. KMT2C was the top gene mutated when comparing differential mutation rates from this data.

To explore the relationship between KMT2C and EC, we transfected 12Z endometrial epithelial cells with KMT2C siRNA to induce transient knockdown and performed western blots with the transfected protein lysates. Additionally, we transfected cells with plasmids containing green fluorescent protein (GFP), Cas9, and 3 different guide RNAs targeting KMT2C to generate stable knockouts. Flow cytometry isolated the GFP+ cells. Using those isolated 12Z CRISPRCas9 knockouts, we performed a final western blot.

KMT2C knockdown led to decreased HER2 expression. KMT2C knockdown increased Arid1a expression and minimally increased Snail and Slug expression. GFP expression…

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free